Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of AZD4144 Formulations and Food/Omeprazole Effect
NCT06948006Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2025
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of AZD4144 in atherosclerotic cardiovascular disease (ASCVD) and chronic kidney disease (CKD) (2 arms), sponsored by AstraZeneca. Primary endpoints: Area under concentration-time curve from time 0 to infinity, Area under concentration-curve from time 0 to the last quantifiable concentration and 1 more. Started Apr 2025; status: completed.
02
Drugs
AZD4144
03
Conditions
atherosclerotic cardiovascular disease (ASCVD)chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT06948006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06948006.